Clinical Trials & Research

View Open Trials

Bladder

  • INCB054828 Urothelial FGF/FGFR

    A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)


  • Ph2 MOXR0916+Atezo Urothelial

    A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXR0916 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY (GO39590)


  • RdDbBlnd NivovsPlbo HighRiskMI Urothl

    A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma- Bristol-Myers Squibb CA209-274


  • Pembrolizumab NMIBC Ref/Intol to BCG

    A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy (MK-3475 057)


Breast

  • Cape/tras +/- ONT-380 HER2+ mBC

    Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206)


  • Cape+BKM120 MBC with Brain met

    Phase II Multicenter Single-arm Study of BKM120 plus Capecitabine for Breast Cancer Patients with Brain Metastases


  • Alpelisib+Ful v Placbo+Ful HER2- Br

    USO 15020 SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment - Novartis CBYL719C2301


Leukemia

  • ACP196 relap CLL & Intoler of Ibrut

    A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208)


Lung (Non Small Cell)

  • Ph3 Nivo vs Plat-Doublet chemo NSCLC

    Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)


  • Maint Abrax/BSC post induct Sqm NSCLC

    A Phase III, randomized, open-label, multi-center, safety and efficacy study to evaluate nab-paclitaxel (Abraxane) as maintenance treatment after induction with nab-paclitaxel plus carboplatin in subjects with squamous cell non-small cell lung cancer (NSCLC) (ABI-007-NSCL-003)


  • Nivo Dose Freq in Prev Tx NSCLC

    A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384- CA209384)


  • Brigatinib v Criz ALK+NSCLC ALTA 1L

    USO 15231 A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301


  • BSC +/- LAN in Lung NETs [SPINET]

    USO 15079 A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 mg plus BSC vs. Placebo plus BSC for Tumor Control in Subjects with Well-Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumors (Spinet) - Ipsen A-US-52030-328


  • Nivo+SOC Recurrent NSCLC

    CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies


  • S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung

    S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer


Lung (Small Cell)

  • Ph2 Rovalpituzumab 3L Rel SCLC [TRINITY]

    USO 15129 An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY) - Stemcentrx SCRX001-002


Lymphomas

Melanoma

Myelomas

  • Dara + CyBorD 1L & Relapsed MM [LYRA]

    Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD)in Previously Untreated and Relapsed Subjects with Multiple Myeloma (54767414MMY2012)


  • Len/Dex +/- Keytruda Transp inelig 1L MM

    A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185)


  • Keytruda + Pom/Dex 3L R/R MM

    USO 15143 A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM). (KEYNOTE 183)


Other

  • ATLAS Biologic Samples/Analysis Study

    Non-interventional, research evaluation of functional T-cell responses to tumor-associated mutations identified among solid tumors by ATLAS™ (ATL-009-S01)


  • The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

    The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.


  • Nivo in Advanced/Met Malignancies

    An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)


  • Riva v placebo High VTE risk (Cassini)

    USO 15026 Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)


Prostate

  • Ph3 aPDL1/Atezo+Enza mCRPC

    A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESISINHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN - Roche CO39385


  • ARN509+ADT vs ADT mHSPC

    A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormone-sensitive Prostate Cancer (mHSPC)- Aragon/Janssen 56021927PCR3002 (TITAN)


  • Enzal +/- PI3 Kinase/mTOR inhib mCRPC

    A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer (GU 115/I6A-MC-CBBD)


Renal

  • Avelumab+axitinib vs sutent 1L RCC

    USO 15197 A phase 3, multinational, randomized, open-label, parallel-arm study of Avelumab (MSB0010718C) in combination with Axitinib (Inlyta®) versus Sunitinib (Sutent®) monotherapy in the first-line treatment of patients with advanced renal cell carcinoma (B9991003)


  • Avelumab+axitinib vs sutent 1L RCC

    USO 15178 A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma (AV-951-15-303)


  • Axitinib +/- Dalantercept adv RCC [DART]

    A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma